Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China

Haemophilia

Volumn 13, Issue 4, 2007, Pages 351-356

  Shi, J ^a   Zhao, Y ^b   Wu, J ^c   Sun, J ^d   Wang, L ^e   Yang, Renchi ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

^d FIRST MILITARY MEDICAL UNIVERSITY   (China)

^e Bayer HealthCare Company Limited   (China)

Author keywords

Clinical trial; Haemophilia A; Recombinant factor VIII

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; SUCROSE;

ADOLESCENT; ADULT; ARTICLE; CHINA; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; HEMOPHILIA A; HEMOSTASIS; HUMAN; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; ADULT; CHILD; CHINA; DRUG EVALUATION; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; MIDDLE AGED; RISK FACTORS; SUCROSE;

EID: 34447265719     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01472.x     Document Type: Article

References (24)

1. Evatt BL. The tragic history of AIDS in the hemophilia population, 1982-1984. J Thromb Haemost 2006; 4: 2295-301.
2. World Health Organization. 2005 Update on the HIV/AIDS Epidemic and Response in China. Accessed January 24, 2006: http://www.chinaids.org.cn: Ministry of Health, People's Republic of China, Joint United Nations Programme on HIV/AIDS, World Health Organization, 2005.
3. Zhang L, Li H, Zhao H et al. Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute. Haemophilia 2003; 9: 696-702.
4. Brackmann HH, Oldenburg J, Eis-Hubinger AM et al. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center. Vox Sang 1994; 67 (Suppl. 1): 3-7; discussion 8.
5. Chudy M, Budek I, Keller-Stanislawski B et al. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol 1999; 57: 91-9.
6. Jee YM, Go U, Cheon D et al. Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea. Epidemiol Infect 2006; 134: 87-93.
7. Kedda MA, Kew MC, Cohn RJ et al. An outbreak of hepatitis A among South African patients with hemophilia: Evidence implicating contaminated factor VIII concentrate as the source. Hepatology 1995; 22: 1363-7.
8. Mannucci PM, Gdovin S, Gringeri A et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994; 120: 1-7.
9. Robertson BH, Alter MJ, Bell BP et al. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission. Biologicals 1998; 26: 95-9.
10. Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573-9.
11. Vermylen J, Peerlinck K. Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang 1994; 67 (Suppl. 4): 8-11; discussion 24-6.
12. Schlesinger KW, Ragni MV. Safety of the new generation recombinant factor concentrates. Expert Opin Drug Saf 2002; 1: 213-23.
13. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy -International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
14. Kreuz W, Escuriola Ettingshausen C, Funk M et al. Prevention of joint damage in hemophilic children with early prophylaxis. Orthopade 1999; 28: 341-6.
15. Scharrer I, Brackmann HH, Sultan Y et al. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000; 6: 614-8.
16. Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: A long-term, multicentre clinical study in Japan. Haemophilia 2001; 7: 242-9.
17. Kasper CK. Hemophilia of Georgia, U.S.A. Protocols for the treatment of haemophilia and von Willebrand disease. Haemophilia 2000; 6 (Suppl. 1): 84-93.
18. Kasper CK, Aledort L, Aronson D et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
19. Berntorp E, Nilsson IM, Ljung R, Widell A. Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet 1990; 335: 1531-2.
20. Kasper CK, Lusher JM. Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee. Transfusion 1993; 33: 422-34.
21. Grosse-Bley A, Eis-Hubinger AM, Kaiser R et al. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Thromb Haemost 1994; 72: 503-7.
22. Chamberland M, Khabbaz RF. Emerging issues in blood safety. Infect Dis Clin North Am 1998; 12: 217-29.
23. Lee CA, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Semin Hematol 2006; 32 (Suppl. 2): 10-4.
24. Kreuz W, Gill JC, Rothschild C et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: Results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67.